Table E2.

Preoperative data

Study	Study period	TAVR valve explant, n	TAVR valve implant, n	Days from implant to explant, mean ± SD	STS-PROM at implant, %, mean ± SD	STS-PROM at explant, %, mean ± SD	NHYA III/IV at implant, n	NHYA III/IV at explant, n	Previous cardiac surgery, n	Balloon-expandable valve, n	Self-expandable valve, n
Mangner et al, 20188	2008-2017	20	N/A	276 ± 150	N/A	N/A	N/A	16	N/A	13	7
Jawitz et al, 20209∗	2011-2015	N/A	N/A	140.3 ± 106.6	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Nakazato et al, 202010	2009-2019	4	773	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Hirji et al, 202011	2012-2017	227	137,354	223 ± 95	N/A	N/A	N/A	N/A	55	N/A	N/A
Tang et al, 202012	2010-2020	269	N/A	444.75 ± 245.1	7.3 ± 8.9	N/A	170	N/A	103	137	132
Fukuhara et al, 202113†	2011-2019	N/A	N/A	N/A	3.6 ± 0.7	N/A	14	17	N/A	N/A	N/A
Brescia et al, 202114‡	2019-2020‡	21	3025	487 ± 690	7.3 ± 5.7	18.8 ± 20.5	N/A	17	11	4	17
Fukuhara et al, 202115	2011-2018	782	200,000	N/A	N/A	8.5 ± 8.9	N/A	431	495	318	77
Malvindi et al, 202116	N/A	13	N/A	N/A	N/A	N/A	N/A	N/A	N/A	11	2
Fukuhara et al, 202117§	2019§	189	N/A	N/A	N/A	5.8 ± 5.0	N/A	82	101	110	79

TAVR, Transcatheter aortic valve replacement; SD, standard deviation; STS-PROM, Society of Thoracic Surgeons predicted risk of mortality; NYHA, New York Heart Association; N/A, not applicable.

^∗All data were excluded owing to potential duplication with reference 15 except for days from implant to explant variable.

^†All data were excluded owing to potential duplication with reference 15 except for STS-PROM at implant, NYHA III/IV at implant and explant variables.

^‡Data between 2012 and 2018 were excluded owing to potential duplication with references 13 and 15.

^§Data between 2016 and 2018 were excluded owing to duplication with reference 15.